Pfizer Inc. (PFE)
3 Bargain-Priced Growth Stocks for Fall 2024
While market volatility may initially unsettle investors, it presents an opportunity to capitalize on discounted investment prospects. While the current bull market has favored some sectors, it hasn't been universally beneficial, leaving a trail of high-quality growth stocks facing significant price declines.
Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's.
Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine
The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.
Pfizer Stock: Graham P/E Shows Large Discounts
I view Pfizer Inc. as a leader in a defensive sector under temporary ROCE pressure. Its profit recovery and growth prospects are substantially underestimated by the prevailing market consensus. Even assuming the market's pessimistic consensus outlook, it is discounted by more than 10% from the Graham P/E.
Pfizer: Look Beyond COVID-19 And The Patent Cliffs - Robust Long-Term Tailwinds
PFE's bullish support has already been observed at the $25s, with the worst seemingly well behind us. Its core portfolio continues to generate robust growth at +14% YoY in FQ2'24 (excluding Comirnaty and Paxlovid), with Seagen's therapies already at $2.92B in annualized revenues. FY2025 is likely to bring forth an improved YoY comparison as well, with PFE's 3Y cost optimization program expected to boost their gross/ operating margins to pre-pandemic levels.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 Incredibly Cheap Growth Stocks to Buy Now
Stock market prices don't tell you everything, and that's certainly true with these businesses. Pfizer is paving the way to future growth, but investors might need to be patient.
Why Is Pfizer (PFE) Down 5.9% Since Last Earnings Report?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
Why Walgreens Boots Alliance Plunged Today
Major drugmakers Pfizer and Eli Lilly made major direct-to-consumer announcements. While Walgreens was named as a partner for Pfizer's new direct health platform, it stands to potentially lose out on retail drug sales.
Healthy Returns: What to know about the latest round of Pfizer, Moderna Covid vaccines
A brand new round of Covid shots from Pfizer and Moderna is about to reach Americans. Meanwhile, CNBC tested out Dexcom's new CGM Stelo.
Pfizer launches new website for migraine, respiratory offerings
Pfizer Inc is launching a new website to promote and improve access to its health care offerings for migraine and respiratory illnesses.
